Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.AU |
First Approval Date01 May 2024 |
|
MechanismMuscle-type nAChRs agonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date13 Jan 1984 |
100 Clinical Results associated with Johnson & Johnson Pacific Pty Ltd.
0 Patents (Medical) associated with Johnson & Johnson Pacific Pty Ltd.
100 Deals associated with Johnson & Johnson Pacific Pty Ltd.
100 Translational Medicine associated with Johnson & Johnson Pacific Pty Ltd.